Reuters
Published Feb 15, 2021 08:57PM ET
Updated Feb 16, 2021 12:35AM ET
SYDNEY (Reuters) - Australia's medical regulator granted provisional approval for AstraZeneca (NASDAQ:AZN) Plc's COVID-19 vaccine on Tuesday, bolstering a national inoculation programme it plans to begin rolling out next week.
The vaccine boost came as Australia's second-most populous state neared the likely end of a five-day snap lockdown sparked by a fresh cluster of cases.
The federal government says it has ordered enough of the AstraZeneca vaccine, which will mostly be manufactured in Australia, to cover the country's population of 25 million people.
It has also ordered enough doses of a vaccine jointly developed by Pfizer Inc (NYSE:PFE) and BioNTech, which is being manufactured offshore, for a fifth of the population.
"Australia now has two safe and effective COVID-19 vaccines available," Prime Minister Scott Morrison said in a televised news conference.
Chief Medical Officer Paul Kelly has previously acknowledged concerns about the relatively low efficacy of the AstraZeneca vaccine at around 62%, conceding it may not be enough to achieve herd immunity.
The first batch of the Pfizer-BioNTech vaccine, which has a 95% efficacy rate and has already been approved, arrived in Australia on Monday and authorities have planned the first inoculations for Feb. 22.
The first batch of the AstraZeneca vaccine, which will be manufactured overseas, is expected to arrive in March. The bulk of the AstraZeneca vaccine will subsequently be manufactured in Australia, which authorities have said will protect the country from demand shock abroad.
While countries including the United States and Britain were quicker to approve vaccines, using emergency status, Australia waited until it more complete testing data to grant provisional approval.
Meanwhile, Victoria state, home to a quarter of Australia's population, was on track to end a strict lockdown on Wednesday, authorities said, after reporting just two new infections in the previous 24 hours.
"This strategy is working," state premier Daniel Andrews told reporters. "We are well-placed to be able to make changes tomorrow night. These next 24 hours will be crucial."
Victoria went into its third lockdown on Friday after an outbreak linked to a quarantine hotel, involving 19 cases.
The lifting of lockdown means the Australian Open tennis tournament, which is being held in the state capital Melbourne, may resume admitting spectators who were barred during lockdown.
New South Wales, the country's most populous state, recorded its 30th day in a row without a locally acquired COVID-19 case.
Australia has reported a total of just under 29,000 COVID-19 cases and 909 deaths, with border closures and speedy tracking systems helping keep numbers relatively low compared with other developed countries.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.